Delving into the Latest Updates on Nantong Huashan Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Objective: To determine the content of m-aminoglutethimide, the key impurity in aminoglutethimide with an HPLC method.Methods: Chromatog. was performed on a Waters Spherlsorb column (4.6 mm × 150 mm, 5 μm), with a mixture of pH 5.0 acetate buffer: MeOH (75:25) as the mobile phase.The detection wavelength was 240 nm.Results: The content of m-aminoglutethimide in aminoglutethimide is < 1.0%.The calibration curve was linear at 0.025-0.150 μg (n = 5, r = 0.999 8), and the average rate of recovery was 100.7% (n = 5, relative standard deviation = 1.33%).Conclusion: The method is accurate, sensitive, reliable and could be used as the limit test of m-aminoglutethimide in aminoglutethimide.

100 Deals associated with Nantong Huashan Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Nantong Huashan Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

Login to view more data